Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator eftilagimod alpha (efti) with avelumab in patients with advanced solid tumours. Avelumab is the big pharma pair’s investigational anti-PD-L1 immune checkpoint inhibitor (ICI). We view the additional validation from big pharma is as a very positive development for Immutep, which could bring the added bonus of early identification of additional target indications. We maintain our valuation at A$510m or A$0.17/share.
https://www.edisoninvestmentresearch.com/research/report/immutep314382/full
17c Target - Edison
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
